← All trials
NCT06431113
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 27, 2024
- Primary completion
- Apr 1, 2025
- Completion date
- May 1, 2025
- First posted
- May 28, 2024
- Last posted
- May 29, 2024
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of PaviaLead sponsor
- University of Roma La SapienzaCollaborator
- University of PaviaSponsor investigator
- University of Naples Frederico IICollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.